Ameriprise’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-862,226
| Closed | -$6.79M | – | 4118 |
|
|
2025
Q3 | $6.79M | Buy |
+862,226
| New | +$6.14M | ﹤0.01% | 2193 |
|
|
2025
Q2 | – | Sell |
-285,804
| Closed | -$2.33M | – | 4020 |
|
|
2025
Q1 | $2.33M | Sell |
285,804
-117,323
| -29% | -$1.09M | ﹤0.01% | 2815 |
|
|
2024
Q4 | $3.8M | Buy |
403,127
+16,179
| +4% | +$168K | ﹤0.01% | 2551 |
|
|
2024
Q3 | $4.13M | Buy |
386,948
+6,161
| +2% | +$67.1K | ﹤0.01% | 2504 |
|
|
2024
Q2 | $3.78M | Buy |
380,787
+8,391
| +2% | +$86.1K | ﹤0.01% | 2506 |
|
|
2024
Q1 | $4.39M | Sell |
372,396
-156,978
| -30% | -$2.01M | ﹤0.01% | 2445 |
|
|
2023
Q4 | $7.51M | Buy |
529,374
+110,120
| +26% | +$1.25M | ﹤0.01% | 2028 |
|
|
2023
Q3 | $5.1M | Sell |
419,254
-13,652
| -3% | -$176K | ﹤0.01% | 2270 |
|
|
2023
Q2 | $5.44M | Sell |
432,906
-25,462
| -6% | -$302K | ﹤0.01% | 2284 |
|
|
2023
Q1 | $5.08M | Buy |
458,368
+122,904
| +37% | +$1.51M | ﹤0.01% | 2315 |
|
|
2022
Q4 | $4.09M | Sell |
335,464
-6,620
| -2% | -$74.5K | ﹤0.01% | 2436 |
|
|
2022
Q3 | $3.57M | Sell |
342,084
-70,879
| -17% | -$790K | ﹤0.01% | 2463 |
|
|
2022
Q2 | $4.43M | Buy |
412,963
+78,189
| +23% | +$644K | ﹤0.01% | 2372 |
|
|
2022
Q1 | $3.17M | Buy |
334,774
+24,267
| +8% | +$228K | ﹤0.01% | 2709 |
|
|
2021
Q4 | $3.59M | Buy |
310,507
+53,292
| +21% | +$594K | ﹤0.01% | 2687 |
|
|
2021
Q3 | $2.46M | Buy |
257,215
+52,237
| +25% | +$534K | ﹤0.01% | 2795 |
|
|
2021
Q2 | $1.98M | Sell |
204,978
-39,363
| -16% | -$384K | ﹤0.01% | 2936 |
|
|
2021
Q1 | $2.41M | Sell |
244,341
-11,569
| -5% | -$179K | ﹤0.01% | 2786 |
|
|
2020
Q4 | $5.91M | Buy |
255,910
+46,563
| +22% | +$952K | ﹤0.01% | 2155 |
|
|
2020
Q3 | $2.96M | Sell |
209,347
-67,494
| -24% | -$984K | ﹤0.01% | 2433 |
|
|
2020
Q2 | $4.17M | Sell |
276,841
-91,570
| -25% | -$1.12M | ﹤0.01% | 2195 |
|
|
2020
Q1 | $3.4M | Buy |
368,411
+157,726
| +75% | +$1.5M | ﹤0.01% | 2174 |
|
|
2019
Q4 | $2.05M | Sell |
210,685
-824,361
| -80% | -$7.55M | ﹤0.01% | 2718 |
|
|
2019
Q3 | $8.3M | Buy |
1,035,046
+45,269
| +5% | +$491K | ﹤0.01% | 1843 |
|
|
2019
Q2 | $12.4M | Buy |
989,777
+9,575
| +1% | +$121K | 0.01% | 1564 |
|
|
2019
Q1 | $13.3M | Buy |
980,202
+8,951
| +0.9% | +$109K | 0.01% | 1450 |
|
|
2018
Q4 | $9.3M | Sell |
971,251
-1,636,497
| -63% | -$18M | ﹤0.01% | 1666 |
|
|
2018
Q3 | $31.5M | Buy |
2,607,748
+8,234
| +0.3% | +$115K | 0.01% | 995 |
|
|
2018
Q2 | $40.6M | Buy |
2,599,514
+524,979
| +25% | +$7.94M | 0.02% | 768 |
|
|
2018
Q1 | $31.2M | Buy |
+2,074,535
| New | +$31.6M | 0.01% | 892 |
|
|
2016
Q4 | – | Sell |
-10,034
| Closed | -$75K | – | 3904 |
|
|
2016
Q3 | $75K | Sell |
10,034
-2,058
| -17% | -$13.9K | ﹤0.01% | 3680 |
|
|
2016
Q2 | $66K | Sell |
12,092
-1,256
| -9% | -$8.78K | ﹤0.01% | 3664 |
|
|
2016
Q1 | $113K | Buy |
13,348
+1,179
| +10% | +$8.35K | ﹤0.01% | 3607 |
|
|
2015
Q4 | $118K | Sell |
12,169
-121,225
| -91% | -$1.09M | ﹤0.01% | 3725 |
|
|
2015
Q3 | $1.87M | Sell |
133,394
-65,130
| -33% | -$1.02M | ﹤0.01% | 2658 |
|
|
2015
Q2 | $2.82M | Buy |
198,524
+9,959
| +5% | +$120K | ﹤0.01% | 2540 |
|
|
2015
Q1 | $2.05M | Sell |
188,565
-47,474
| -20% | -$418K | ﹤0.01% | 2589 |
|
|
2014
Q4 | $1.96M | Buy |
236,039
+9,236
| +4% | +$63.4K | ﹤0.01% | 2573 |
|
|
2014
Q3 | $1.35M | Buy |
+226,803
| New | +$1.19M | ﹤0.01% | 2664 |
|
|
2013
Q4 | – | Sell |
-1,895
| Closed | -$4K | – | 5237 |
|
|
2013
Q3 | $4K | Sell |
1,895
-10
| -0.5% | -$25 | ﹤0.01% | 5284 |
|
|
2013
Q2 | $4K | Buy |
+1,905
| New | +$5.86K | ﹤0.01% | 5193 |
|
Other funds holding FOLD
HI
PCM
BG
PA
Ameriprise's FOLD Position: Q4 2025 in Review
Ameriprise sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 862,226 shares — an estimated $6.79M sold.
Ameriprise first reported a position in FOLD in Q2 2013 and held it in 41 quarters. The position peaked at $40.6M in Q2 2018. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.
- Ameriprise reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
- Ameriprise sold 862,226 Amicus Therapeutics shares in Q4 2025, an estimated $6.79M.
- Ameriprise first reported a position in Amicus Therapeutics in Q2 2013 and held it in 41 quarters.
- Ameriprise's Amicus Therapeutics position peaked at $40.6M in Q2 2018.
- 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.
Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.